{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Seok J"],"funding":["Ministry of Health & Welfare, Republic of Korea","Ministry of Health &amp; Welfare, Republic of Korea"],"pagination":["671"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12673732"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["<h4>Background</h4>Atopic dermatitis (AD) is a chronic skin condition affecting patients' well-being, but conventional treatments have limitations. Mesenchymal stem cells (MSCs) present a promising option for AD therapy, though large-scale clinical studies are scarce. This study aimed to assess the efficacy and safety of autologous adipose tissue-derived MSC (AtMSC) in moderate to severe AD refractory to conventional treatments.<h4>Methods</h4>This multicenter, randomized, single-blind, placebo-controlled, phase 2 trial included 114 participants. Participants received two intravenous injections of AtMSCs or placebo at 4-week intervals. Clinical assessments, comprising Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), and Investigator's Global Assessment (IGA), were"],"journal":["Stem cell research & therapy"],"pubmed_title":["Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial."],"pmcid":["PMC12673732"],"funding_grant_id":["RS-2024-00406957"],"pubmed_authors":["Seo YJ","Kim SY","Son SW","Shin MK","Park KY","Lee DH","Lee SH","Seo JS","Lee WG","Cho S","Seok J","Seo SJ"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial.","description":"<h4>Background</h4>Atopic dermatitis (AD) is a chronic skin condition affecting patients' well-being, but conventional treatments have limitations. Mesenchymal stem cells (MSCs) present a promising option for AD therapy, though large-scale clinical studies are scarce. This study aimed to assess the efficacy and safety of autologous adipose tissue-derived MSC (AtMSC) in moderate to severe AD refractory to conventional treatments.<h4>Methods</h4>This multicenter, randomized, single-blind, placebo-controlled, phase 2 trial included 114 participants. Participants received two intravenous injections of AtMSCs or placebo at 4-week intervals. Clinical assessments, comprising Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), and Investigator's Global Assessment (IGA), were","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-05T22:20:48.485Z","creation":"2026-05-22T03:16:14.414Z"},"accession":"S-EPMC12673732","cross_references":{"pubmed":["41331725"],"doi":["10.1186/s13287-025-04763-y"]}}